Início › Leucemia Linfocítica Crônica › Virgínia
Ensaios clínicos de Leucemia Linfocítica Crônica em Virgínia
12 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Virgínia.
Cidades em Virgínia
Texto oficial do estudo (Inglês)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Health Tappahannock Hospital, Tappahannock
RecrutandoFase 3
Idades 65 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- e mais 7
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Ballad Health Cancer Care - Bristol, Bristol
- Ballad Health Cancer Care - Norton, Norton
- VCU Massey Cancer Center at Stony Point, Richmond
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia), Roanake
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- University of Virginia Cancer Center ( Site 5402), Charlottesville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- University of Virginia Cancer Center ( Site 0040), Charlottesville
- Inova Schar Cancer Institute ( Site 0015), Fairfax
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest VA, Norfolk
- Virginia Oncology Associates, Norfolk
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Virginia Cancer Specialists, Fairfax
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT07516093A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Virginia Cancer Institute, Richmond
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05254743A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Virginia Oncology Associates, Hampton
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Virginia Cancer Specialists - Fairfax /ID# 268155, Fairfax
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.